Literature DB >> 8597678

Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework.

.   

Abstract

OBJECTIVE: To compare the acceptability and symptomatic and metabolic effects of two regimens of hormone replacement therapy in women with hysterectomy.
DESIGN: Randomised, double blind comparison.
SETTING: Seven group practices in the Medical Research Council's general practice research framework.
SUBJECTS: 321 women with hysterectomy aged 35-59.
INTERVENTIONS: Hormone replacement therapy with (a) conjugated equine oestrogen 625 micrograms daily alone or (b) conjugated equine oestrogen 625 micrograms daily plus the progestogen norgestrel 150 micrograms daily for the last 12 days of the 'cycle.' MAIN OUTCOME MEASURES: Changes in blood pressure, weight, symptoms, and haemostatic and lipid values.
RESULTS: After two years 36% (57/158) of women randomly allocated to take oestrogen alone had discontinued treatment as compared with 30% (49/163) of women allocated to take oestrogen plus progestogen. Smokers were more likely to withdraw than non-smokers. There were no clear differences between the two groups in symptoms often attributed to hormone replacement therapy or in blood pressure or weight. At one year low density lipoprotein cholesterol concentrations had fallen substantially in both groups. High density lipoprotein cholesterol concentrations rose to significantly higher values in women taking oestrogen alone compared with those taking oestrogen plus progestogen, though triglyceride concentrations and factor VII activity were also significantly higher in this group. Fibrinogen concentration tended to fall, though not significantly, in both groups, possibly more in women taking oestrogen alone.
CONCLUSIONS: Oestrogen plus progestogen was no less well tolerated than oestrogen alone. There was a fairly even balance between possibly beneficial and adverse effects of the two regimens on lipid concentrations and coagulability. Concern that the combined regiment may not have the cardioprotective effects ascribed to oestrogen alone can to some extent be allayed, with reassurance for the growing numbers of women with intact uteri using the combined regiment. Misgivings about the combined regiment in women with hysterectomy on the grounds of its acceptability and its effects on lipid values may also be unfounded.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8597678      PMCID: PMC2349976     

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  25 in total

1.  Haemostatic changes that constitute the hypercoagulable state.

Authors:  G J Miller; H C Wilkes; T W Meade; K A Bauer; S Barzegar; R D Rosenberg
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

2.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.

Authors:  M J Stampfer; G A Colditz
Journal:  Prev Med       Date:  1991-01       Impact factor: 4.018

3.  Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework.

Authors:  H C Wilkes; T W Meade
Journal:  BMJ       Date:  1991-06-01

4.  Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

Authors:  T W Meade; S Mellows; M Brozovic; G J Miller; R R Chakrabarti; W R North; A P Haines; Y Stirling; J D Imeson; S G Thompson
Journal:  Lancet       Date:  1986-09-06       Impact factor: 79.321

5.  Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause.

Authors:  K F Gangar; S Vyas; M Whitehead; D Crook; H Meire; S Campbell
Journal:  Lancet       Date:  1991-10-05       Impact factor: 79.321

6.  Fibrinogen and risk of cardiovascular disease. The Framingham Study.

Authors:  W B Kannel; P A Wolf; W P Castelli; R B D'Agostino
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

7.  Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.

Authors:  J C Gallagher; W T Kable; D Goldgar
Journal:  Am J Med       Date:  1991-02       Impact factor: 4.965

8.  Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors.

Authors:  A R Folsom; K K Wu; C E Davis; M G Conlan; P D Sorlie; M Szklo
Journal:  Atherosclerosis       Date:  1991-12       Impact factor: 5.162

9.  Hypertriglyceridemia and regulation of fibrinolytic activity.

Authors:  L Mussoni; L Mannucci; M Sirtori; M Camera; P Maderna; L Sironi; E Tremoli
Journal:  Arterioscler Thromb       Date:  1992-01

10.  The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement.

Authors:  M Falkeborn; I Persson; H O Adami; R Bergström; E Eaker; H Lithell; R Mohsen; T Naessén
Journal:  Br J Obstet Gynaecol       Date:  1992-10
View more
  9 in total

Review 1.  "Extracts from "Clinical evidence": Menopausal symptoms.

Authors:  J Rymer; E P Morris
Journal:  BMJ       Date:  2000-12-16

Review 2.  Menopausal symptoms.

Authors:  Nikolaos Burbos; Edward P Morris
Journal:  BMJ Clin Evid       Date:  2011-06-15

Review 3.  Menopausal symptoms.

Authors:  Edward P Morris; Nikolaos Burbos
Journal:  BMJ Clin Evid       Date:  2010-02-25

Review 4.  General internal medicine update. Information clinicians and teachers need to know.

Authors:  J V Sheffield; E B Larson
Journal:  J Gen Intern Med       Date:  1996-10       Impact factor: 5.128

5.  Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study.

Authors:  A J Welton; M R Vickers; J A Cooper; T W Meade; T M Marteau
Journal:  BMJ       Date:  1999-04-24

6.  The pharmacoeconomics of hormone replacement therapy.

Authors:  D J Torgerson; D M Reid
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

Review 7.  Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women.

Authors:  Kwang Kon Koh
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

8.  The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial.

Authors:  Madge R Vickers; Jeannett Martin; Tom W Meade
Journal:  BMC Womens Health       Date:  2007-02-26       Impact factor: 2.809

Review 9.  Dyslipidemia in women: etiology and management.

Authors:  Binh An P Phan; Peter P Toth
Journal:  Int J Womens Health       Date:  2014-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.